EUVIMEDObjevte EUVIMED
Crossref

Decreased plasma exposure of clopidogrel active metabolite in rats after long‐term treatment with clopidogrel

Yani Wang, Yingrui Liu, Hongwei Yao, Xue Chen, Yantong Sun, Yingjie Guo iD

Biopharmaceutics & Drug Disposition · 2023

DOI: 10.1002/bdd.2349 ↗

At a glance

Journal article in Biopharmaceutics & Drug Disposition, 2023. Written by Yani Wang and 5 co-authors. Institution: Key Laboratory for Molecular Enzymology & Engineering of the Ministry of Education, Jilin University, Changchun, China. Major MEDLINE topics: Platelet Aggregation Inhibitors, Platelet Aggregation. 18 references. Funded by: National Major Science and Technology Projects of China.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Clopidogrel (Clop) is oxidized by cytochrome P450s (CYPs) to an active thiol metabolite, Clop‐AM, to inhibit platelet activation and aggregation. As an irreversible inhibitor of CYP2B6 and CYP2C19, clopidogrel may inhibit its own metabolism after long‐term administration. The study compared the pharmacokinetic profiles of clopidogrel and its metabolites in rats receiving a single or a 2 week administration of Clop. The mRNA and protein levels of hepatic clopidogrel‐metabolizing enzymes and their enzymatic activities were analyzed to explore their contribution to any altered plasma exposure of Clop and its metabolites. The results showed that long‐term treatment with clopidogrel significantly decreased the AUC (0‐t) and C max values of Clop‐AM in rats, accompanied with markedly impaired catalytic activities of Clop‐metabolizing CYPs including CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4. It suggests that consecutive administration of Clop to rats decreases hepatic CYPs activities, which may, in turn, inhibit clopidogrel metabolism and then reduce Clop‐AM plasma exposure. Therefore, long‐term treatment with clopidogrel has the potential to reduce its anti‐platelet activity and to increase the risk of drug–drug interaction.

Subjects

MeSH terms (MEDLINE)

Platelet Aggregation InhibitorsPlatelet AggregationRatsAnimalsClopidogrelCytochrome P-450 CYP2C19Cytochrome P-450 CYP2B6Cytochrome P-450 Enzyme System

Author keywords

active metaboliteclopidogrelcytochrome P450slong-term treatmentpharmacokinetics

Substances

ClopidogrelPlatelet Aggregation InhibitorsCytochrome P-450 CYP2C19Cytochrome P-450 CYP2B6Cytochrome P-450 Enzyme System

Authors and institutions

  • Key Laboratory for Molecular Enzymology & Engineering of the Ministry of Education, Jilin University, Changchun, China.
  • School of Life Sciences, Jilin University, Changchun, China.
  • School of Pharmaceutical Sciences, Jilin University, Changchun, China.
  • National Engineering Laboratory of AIDS Vaccine, Jilin University, Changchun, China.

ORCID profiles: Yingjie Guo

Funding

  • National Major Science and Technology Projects of China

Cite

APA

Wang, Y., Liu, Y., Yao, H., Chen, X., Sun, Y., & Guo, Y. (2023). Decreased plasma exposure of clopidogrel active metabolite in rats after long‐term treatment with clopidogrel. Biopharmaceutics & Drug Disposition. https://doi.org/10.1002/bdd.2349

Vancouver

Wang Y, Liu Y, Yao H, Chen X, Sun Y, Guo Y. Decreased plasma exposure of clopidogrel active metabolite in rats after long‐term treatment with clopidogrel. Biopharmaceutics & Drug Disposition. 2023. doi:10.1002/bdd.2349

BibTeX
@article{Wang2023,
  author = {Wang, Yani and Liu, Yingrui and Yao, Hongwei and Chen, Xue and Sun, Yantong and Guo, Yingjie},
  title = {Decreased plasma exposure of clopidogrel active metabolite in rats after long‐term treatment with clopidogrel},
  journal = {Biopharmaceutics & Drug Disposition},
  year = {2023},
  doi = {10.1002/bdd.2349}
}
Start for free →